Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer

被引:114
作者
Chang, TC [1 ]
Lai, CH
Hong, JH
Hsueh, S
Huang, KG
Chou, HH
Tseng, CJ
Tsai, CS
Chang, JT
Lin, CT
Chang, HH
Chao, PJ
Ng, KK
Tang, SGJ
Soong, YK
机构
[1] Chang Gung Mem Hosp, Linkou Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Taoyuan, Taiwan
[2] Chang Gung Mem Hosp, Linkou Med Ctr, Dept Pathol, Taoyuan, Taiwan
[3] Chang Gung Mem Hosp, Linkou Med Ctr, Dept Radiat Oncol, Taoyuan, Taiwan
[4] Chang Gung Mem Hosp, Linkou Med Ctr, Dept Diagnost Radiol, Taoyuan, Taiwan
[5] Chang Gung Mem Hosp, Linkou Med Ctr, Biostat Consulting Ctr, Taoyuan, Taiwan
[6] Chang Gung Med Coll, Taoyuan, Taiwan
关键词
D O I
10.1200/JCO.2000.18.8.1740
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To compare the efficacy of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy with that of radiotherapy (R/T) for bulky early-stage cervical cancer, Patients and Methods: Women with previously untreated bulky (primary tumor greater than or equal to 4 cm) stage IB or IIA non-small-cell carcinoma of the uterine cervix were randomly assigned to receive either cisplatin 50 mg/m(2) and vincristine 1 mg/m(2) for 1 day and bleomycin 25 mg/m(2) for 3 days for three cycles followed by radical hysterectomy (NAC arm) or receive primary pelvic radiotherapy only (R/T arm). The ratio of patient allocation was 6:4 for the NAC and R/T arms. Women with enlarged para-aortic lymph nodes on image study were ineligible unless results of cytologic or histologic studies were negative. Results: Of the 124 eligible patients, 68 in the NAC arm and 52 in the R/T arm could be evaluated. The median duration of follow-up was 39 months. Thirty-one percent of patients in the NAC arm and 27% in the R/T arm had relapse or persistent diseases after treatment, and 21% in each group died of disease. Estimated cumulative survival rates at 2 years were 81% for the NAC arm and 84% for the R/T arm; the 5-year rates were 70% and 61%, respectively. There were no significant differences in disease-free survival and overall survival, Conclusion: NAC followed by radical hysterectomy and primary R/T showed similar efficacy for bulky stage IB or IIA cervical cancer. Further study to identify patient subgroups better suited for either treatment modality and to evaluate the concurrent use of cisplatin and radiation without routine hysterectomy is necessary. J Clin Oncol 18:1740-1747. (C), 2000 by American Society of Clinical Oncology.
引用
收藏
页码:1740 / 1747
页数:8
相关论文
共 45 条
  • [1] ALBERTS DS, 1981, CANCER CLIN TRIALS, V4, P313
  • [2] IDENTIFICATION OF PROGNOSTIC FACTORS AND RISK GROUPS IN PATIENTS FOUND TO HAVE NODAL METASTASIS AT THE TIME OF RADICAL HYSTERECTOMY FOR EARLY-STAGE SQUAMOUS CARCINOMA OF THE CERVIX
    ALVAREZ, RD
    SOONG, SJ
    KINNEY, WK
    REID, GC
    SCHRAY, MF
    PODRATZ, KC
    MORLEY, GW
    SHINGLETON, HM
    [J]. GYNECOLOGIC ONCOLOGY, 1989, 35 (02) : 130 - 135
  • [3] BLOCH B, 1984, CANCER TREAT REP, V68, P891
  • [4] RANDOMIZED TRIAL OF 3 CISPLATIN DOSE SCHEDULES IN SQUAMOUS-CELL CARCINOMA OF THE CERVIX - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
    BONOMI, P
    BLESSING, JA
    STEHMAN, FB
    DISAIA, PJ
    WALTON, L
    MAJOR, FJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (08) : 1079 - 1085
  • [5] BURGHARDT E, 1978, OBSTET GYNECOL, V52, P138
  • [6] NEOADJUVANT CHEMOTHERAPY WITH CISPLATIN, VINCRISTINE, AND BLEOMYCIN AND RADICAL SURGERY IN EARLY-STAGE BULKY CERVICAL-CARCINOMA
    CHANG, HC
    LAI, CH
    CHOU, PC
    TSENG, CJ
    CHANG, TC
    HSUEH, S
    HO, YS
    SOONG, YK
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 30 (04) : 281 - 285
  • [7] Chang TC, 1996, CANCER CHEMOTH PHARM, V37, P279
  • [8] ANALYSIS OF FACTORS CONTRIBUTING TO TREATMENT FAILURES IN STAGE-IB AND STAGE-II-A CARCINOMA OF THE CERVIX
    CHUNG, CK
    NAHHAS, WA
    STRYKER, JA
    CURRY, SL
    ABT, AB
    MORTEL, R
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1980, 138 (05) : 550 - 556
  • [9] A PHASE-II STUDY OF IFOSFAMIDE AND CISPLATIN CHEMOTHERAPY FOR METASTATIC OR RELAPSED CARCINOMA OF THE CERVIX
    COLEMAN, RE
    CLARKE, JM
    SLEVIN, ML
    SWEETENHAM, J
    WILLIAMS, CJ
    BLAKE, P
    CALMAN, F
    WILTSHAW, E
    HARPER, PG
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 27 (01) : 52 - 54
  • [10] Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): A randomized phase III trial
    Curtin, JP
    Hoskins, WJ
    Venkatraman, ES
    Almadrones, L
    Podratz, KC
    Long, H
    Teneriello, M
    Averette, H
    Sevin, BU
    [J]. GYNECOLOGIC ONCOLOGY, 1996, 61 (01) : 3 - 10